No Detail Found!

Therapeutic effect of gefitinib on patients with advanced EGFR- mutation NSCLC

Author(s)
Ailing Xu Three Internal Departments, Anqiu Municipal Hospital,Weifang,China
Haixia Yan Intravenous Drug Dispensing Center, Jiyang District People's Hospital,Ji'nan,China
Tongliang Bu Oncohaematology, Weifang City People's Hospital of Fangzi District,Weifang,China
Abstract
This study aims to study the role of gefitinib on patients with advanced EGFR-mutation NSCLC (Non-Small Cell Lung Cancer). Totally 115 patients with advanced EGFR-mutation NSCLC treated in our hospital were enrolled as research objects. They were randomly divided into control group (n=57) applied with cisplatin + pemetrexed and experimental group (n=58) subject to gefitinib+ cisplatin + pemetrexed, both groups were applied with treatment for 4 cycles. Clinical efficacy: The disease control rate (DCR) was 72.41% in the experimental group, which was higher than that of the control group (54.39%, p<0.05); Serum CEA, CYFRA21-1, MMP-9 levels: after 2 and 4 cycles of treatment, serum CEA, CYFRA21-1, and MMP-9 levels were lower in the experimental group (p<0.05); Immune function: after 2 and 4 cycles of treatment, Th1 cells and Th1/Th2 cell levels were higher in the experimental group, while Th2 cell level was higher in the control group (p<0.05); Angiogenesis related indicators: the levels of VEGF, HIF-1a and sCD105 were lower in the experimental group after 2 and 4 cycles of treatment (p<0.05); (5) Adverse reactions: After 2 and 4 cycles of treatment, the levels of VEGF, HIF-1a, and sCD105 were lower in the experimental group (p<0.05). The application of gefitinib in patients with advanced EGFR-mutation NSCLC can help down-regulate CEA, CYFRA21-1, and MMP-9 levels, inhibit angiopoiesis, enhance immune function, and increase disease control rate.
Publication Details
Page(s) 481-486
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S1, Year: 2021

Request the full text from PASTIC

Keywords
Immune function, eGFR, CYFRA21-1, NSCLC, NSCLC, MMP-9, Gefitinib
References
Bie ZX,Feng L ZX .2018 .Single-center clinical trial of first-line afatinib regimen versus cisplatin combined with pemetrexed regimen in the treatment of advanced non-small cell lung adenocarcinoma with EGFR mutation. Chin. J. Cancer Prevent, 25(10) : 740-745.
Castellanos E,Feld E,Horn L E .2017 .Driven by mutations: The predictive value of mutation subtype in egfr-mutated non-small cell lung cancer. J. Thorac. Oncol., 12(4) : 612-623.
Chen HR,Tian HQ,Chen ZM,Huang XW,Zheng XT,Chen XZ,Lin LZ .2018 .Effectiveness and safety of Kangai injection combined with single-agent chemotherapy in the treatment of elderly advanced non-small cell lung cancer. J. Pract. Med, 34(2) : 316-319.
Dal Bello MG,Filiberti RA,Alama A,Orengo AM,Mussap M,Coco S,Vanni I,Boccardo S,Rijavec E,Genova C,Biello F,Barletta G,Rossi G,Tagliamento M,Magginoi C,Grossi F C .2019 .The role of cea, cyfra21-1 and nse in monitoring tumor response to nivolumab in advanced non-small cell lung cancer (nsclc) patients. J. Transl. Med, 17(1) : 74.
Fang YJ,Pan JL,Lu HF,Jiang YP,Li SL,Hong GB .2019 .Early evaluate the feasibility and reproducibility of sorafenib targeted therapy for hepatocellular carcinoma by volume measurement approach. Chin. J. Radiology, 53(2) : 133-137.
Feng W,Chen X,Guan SX,Zhang L,Huang M,Wang XD .2018 .Correlation between MAPK1 gene polymorphism and gefitinib hepatotoxicity in patients with EGFR-sensitive non-small cell lung cancer. Acta Pharm, 53(5) : 760-764.
Guo G,Li H,Guo Q,Li GF .2016 .The effect of gefitinib on immune function of patients with nonsmall cell lung cancer. Chin. J. Clin. Pharmacol, 32(6) : 505-507.
He WL,Zhang H,Wang YF,Zhou YB,Luo YF,Cui YM,Jiang N,Jiang WT,Wang H,Xu D,Li SH,Wang Z,Chen YS,Sun Y,Zhang Y,Tseng HR,Zou XN,Wang LT,Ke ZF .2018 .Cthrc1 induces non-small cell lung cancer (nsclc) invasion through upregulating mmp-7/mmp-9. , 18(1) : 400.
Leonetti A,Sharma S,Minari R,Perego P,Giovannetti E,Tiseo M .2019 .Resistance mechanisms to osimertinib in egfr-mutated non-small cell lung cancer. Brit. J. Cancer, 121(9) : 725-737.
Lin GH,Lin LZ,Zhang Y,Pei WY,Zeng JC,Zhao WX .2019 .Influence of fire needle stimulation at Sihua acupoints on performance status and Th1/Th2 balance in the patients with advanced non-small cell lung cancer after chemotherapy. Acupuncture Res., 44(2) : 136-139.
Liu T,Xiong Q,Hu Y .2018 .Clinical observation of albumin-bound paclitaxel combined with tegafur in the first-line treatment of elderly patients with advanced pancreatic cancer. J. Mod. Oncol., 26(5) : 722-725.
Peng M,Weng YM,Chen L,Song QB .2018 .Metaanalysis of the efficacy and safety of EGFR-TKI combined chemotherapy versus EGFR-TKI alone in the treatment of EGFR-mutated advanced non-small cell lung cancer. China Cancer, 27(11) : 874-880.
Rafei H,El-Bahesh E,Finianos A,Nassereddine S,Tabbara I .2017 .Immune-based Therapies for Nonsmall Cell Lung Cancer. Anticancer Res., 37(2) : 377-387.
Tian CY,Li FY,Yang J,Zhao Y,Chu GW Y .2018 .Clinical efficacy of gefitinib combined with gemcitabine and cisplatin chemotherapy in treatment of patients with advanced non-small cell lung cancer and its effect on serum tumor markers. Med. J. Chin. People's Liberation Army, 30(4) : 25-28.
Pi Wang J,C Wang J .2018 .Comparison of the efficacy of osimertinib versus pemetrexed combined with platinum-based chemotherapy on patients with EGFR T790M positive non-small cell lung cancer. J. Evidbased Med, 18(1) : 36-39.
Wang XL,Yuan F,Wu XN,Xu MQ .2013 .Characteristics and clinical significance of immune cells in tumor microenvironment of non-small cell lung cancer. J. Clin. Pulm. Med, 18(2) : 282-288.
Wang XM,Chen J,Yao JQ,Guo RH .2018 .The efficacy of gefitinib combined with pericardial perfusion in the treatment of advanced non-small cell lung cancer. Chin. J. Lung Cancer, 21(1) : 37-42.
Wu SG,Shih JY .2018 .Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol. Cancer, 17(1) : 38.
Zeng XQ,Tan M,Ren YF M .2018 .Effects of staged cognitive behavioral intervention on negative emotion and quality of life in patients with non-small cell lung cancer chemotherapy. Chin. J. Clin. Oncol. Rehabil, 25(4) : 484-487.
Zhang D,Yang G,Zhang SG .2015 .The effect of gefitinib on immune function of patients with lung squamous cell carcinoma and its short-term clinical efficacy. Anhui Med, 19(7) : 1367-1370.
Zhang YB,Sun L,Wang JP,Song LJ,Xia JH .2018 .Expression and significance of CHCHD2 and HIF-1α in non-small cell lung cancer. Chin. J. Clin. Exp, 34(11) : 1230-1234.
Zhao S,Qiao WL,Qiu ZX,Li L,Li WM .2018 .Pharmacoeconomics systematic review of gefitinib in the treatment of advanced non-small cell lung cancer. West Chin. Med, 33(1) : 76-83.
Zhou F,Du J,Wang JJ .2017 .Albendazole inhibits hif-1α-dependent glycolysis and vegf expression in non-small cell lung cancer cells. Mol. Cell, 428(1-2) : 171-178.
0

Citations

0

Downloads

8

Views